TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19168206

Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy and lymphadenectomy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy and lymphadenectomy
Number of subjects: 181
Study: 16935686

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 100 mug twice daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 100 mug twice daily (open-label added if symptoms not controlled)
Number of subjects: 200
Study: 12813384

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before incision, 200 mg/hour infusion during surgery)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 49
Study: 10855595

Group type: EXPERIMENTAL
Intervention: Depressed mood and underweight (BMI < 20)
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Not depressed and underweight (BMI < 20)
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Depressed mood and normal weight (BMI 20-24.99)
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Not depressed and normal weight (BMI 20-24.99)
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Depressed mood and overweight (BMI > or = 25)
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Not depressed and overweight (BMI > or = 25)
Number of subjects: 2275
Study: 8707761

Group type: EXPERIMENTAL
Intervention: Adjunctive cytokine and progenitor cell support of hematologic recovery after myelosuppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematopoietic cytokines active on cells of the leukocyte lineages
Number of subjects: 0
Study: 1511228

Group type: EXPERIMENTAL
Intervention: Clonidine or guanfacine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 0
Study: 6359848

Group type: EXPERIMENTAL
Intervention: Oral verapamil
Number of subjects: 30
Study: 30654549

Group type: EXPERIMENTAL
Intervention: Wireless sensor network (WSN) with randomized identifier for location data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media Access Control (MAC) protocol designed and implemented using beacon-slotted ALOHA mechanism
Number of subjects: 0
Study: 28994675

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/kg/h continuous infusion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dopamine 3 μg/kg/min continuous infusion
Number of subjects: 150
Study: 26870843

Group type: EXPERIMENTAL
Intervention: Periodontal dressing containing colophony, zinc oxide and magnesium oxide applied after scaling and root planing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no dressing)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Periodontal dressing
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 28
Study: 25134117

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 318
Study: 22802974

Group type: EXPERIMENTAL
Intervention: 100 µg rSh28GST with aluminium hydroxide (Alum) as adjuvant (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 µg rSh28GST (n=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alum alone (n=8)
Number of subjects: 24
Study: 19006541

Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets 75 mg (on-demand)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lansoprazole capsules 15 mg (on-demand)
Number of subjects: 103
Study: 17768579

Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg/day to 900 mg/day intravenously on the first postoperative day, followed by 400 mg/day orally until hospital discharge or until completing seven days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no prophylaxis with amiodarone)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-randomized individuals (with two or fewer risk factors)
Number of subjects: 68
Study: 15010730

Group type: EXPERIMENTAL
Intervention: Stimulation with phorbol 12‐myristate 13‐acetate and ionomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation for 24 h
Number of subjects: 0
Study: 12169323

Group type: EXPERIMENTAL
Intervention: cnMUPs (concentric needle EMG)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: mMUPs (macro-EMG)
Number of subjects: 21
Study: 11350207

Group type: EXPERIMENTAL
Intervention: D-tagatose (3x15 g daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (sucrose, 3x15 g daily)
Number of subjects: 12
Study: 9229235

Group type: EXPERIMENTAL
Intervention: s/c GLP-1 40 nmol, given three times a day immediately before meals
Number of subjects: 5

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 5
Study: 8235104

Group type: EXPERIMENTAL
Intervention: Diode laser indirect ophthalmoscope (LIO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Argon laser indirect ophthalmoscope (LIO)
Number of subjects: 9
Study: 3306730

Group type: EXPERIMENTAL
Intervention: Hypohydration at 0%, 3%, 5%, and 7% body weight loss
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ad lib drinking during hypohydration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fluid intake prediction
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Thirst sensations
Number of subjects: 7
Study: 29057502

Group type: EXPERIMENTAL
Intervention: Digital photographic reference scales for evaluating facial aging signs
Number of subjects: 750
Study: 27162449

Group type: EXPERIMENTAL
Intervention: Ex‐PRESS device implantation (model P50)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ex‐PRESS group vs Trabeculectomy group
Number of subjects: 26
Study: 25400667

Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) applied three times per day during treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no RJ)
Number of subjects: 13
Study: 23299850

Group type: EXPERIMENTAL
Intervention: Single injection of PRP (Group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Two injections of PRP (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 78
Study: 20225605

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy considerations
Number of subjects: 0
Study: 18461102

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein (Soy+)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein (Soy-)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milk protein (Milk)
Number of subjects: 30
Study: 15937693

Group type: COMPARATOR
Intervention: Appendectomy in UC
Number of subjects: 382

Group type: COMPARATOR
Intervention: Appendectomy in CD
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Smoking in UC
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: OCP and NSAID use in UC
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 382
Study: 12932675

Group type: EXPERIMENTAL
Intervention: Ovarian carcinoma patients
Number of subjects: 40
Study: 10867980

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride 0.2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride 22 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride 0.2 mg + Yohimbine hydrochloride 22 mg
Number of subjects: 16
Study: 9031988

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1590547

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg dose of ethanol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo dose
Number of subjects: 40
Study: 29336029

Group type: EXPERIMENTAL
Intervention: Brain-responsive neurostimulation (RNS System)
Number of subjects: 707
Study: 26547540

Group type: EXPERIMENTAL
Intervention: Adult eczema
Number of subjects: 47611

Group type: EXPERIMENTAL
Intervention: Childhood eczema
Number of subjects: 47611
Study: 25383795

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program: For Parents and Youth Ages 10-14 (SFP 10-14)
Number of subjects: 252
Study: 22594461

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg once daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) 0.4 U/kg once daily
Number of subjects: 54
Study: 20538838

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) 600 mg (healthy control)
Number of subjects: 24
Study: 18335014

Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 10

Group type: COMPARATOR
Intervention: No cooling vest
Number of subjects: 10
Study: 16521032

Group type: EXPERIMENTAL
Intervention: Cocaine infusions (0, 8, 16, and 32 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cocaine infusions (16 mg)
Number of subjects: 14
Study: 12724276

Group type: EXPERIMENTAL
Intervention: VCY2 antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10881609

Group type: EXPERIMENTAL
Intervention: Articulatory suppression with irrelevant speech suffix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrelevant speech during list presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different items as irrelevant speech
Number of subjects: 0
Study: 9505982

Group type: EXPERIMENTAL
Intervention: 15 mg hydrocodone bitartrate with 400 mg ibuprofen
Number of subjects: 120

Group type: COMPARATOR
Intervention: 400 mg ibuprofen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8211428

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3516291

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of apomorphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous administration of apomorphine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31368284

Group type: EXPERIMENTAL
Intervention: Body acupuncture combined with auricular acupuncture
Number of subjects: 111

Group type: COMPARATOR
Intervention: Body acupuncture (control group)
Number of subjects: 111
Study: 29456025

Group type: EXPERIMENTAL
Intervention: Expert-driven e-counseling
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: User-driven e-counseling
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (weekly e-mail newsletter)
Number of subjects: 128
Study: 27088240

Group type: EXPERIMENTAL
Intervention: In-class policy reading and discussion
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: In-class policy reading
Number of subjects: 1195

Group type: COMPARATOR
Intervention: No reading or discussion
Number of subjects: 1195
Study: 24812891

Group type: EXPERIMENTAL
Intervention: Kuanxiong Aerosol (KA), sublingual spray 0.6 mL three times during angina attack
Number of subjects: 780

Group type: COMPARATOR
Intervention: Nitroglycerin Tablet (NT), 0.5 mg sublingually dissolved during angina attack
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Kuanxiong Aerosol (KA)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Nitroglycerin Tablet (NT)
Number of subjects: 780
Study: 23654012

Group type: EXPERIMENTAL
Intervention: Low frequency pulsing electromagnetic field (LFEMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interference currents (IFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medicamentous therapy (Diklofenak 100 mg, 2 tablets per day)
Number of subjects: 60
Study: 20484064

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) with 10 minutes of lower limb ischemia-reperfusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 70
Study: 18797179

Group type: EXPERIMENTAL
Intervention: AIC immunotherapy (6 escalating doses of AIC 0.06-12 microg; n = 12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 19
Study: 15723704

Group type: EXPERIMENTAL
Intervention: Resorbable pins
Number of subjects: 54

Group type: COMPARATOR
Intervention: Resorbable screws
Number of subjects: 54
Study: 12486484

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 45

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 45
Study: 10068011

Group type: EXPERIMENTAL
Intervention: Colles'‐type plaster cast with the wrist immobilised in 20 degrees flexion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colles'‐type plaster cast with the wrist immobilised in 20 degrees extension
Number of subjects: 0
Study: 8635184

Group type: EXPERIMENTAL
Intervention: 200 mg of tolcapone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 mg of tolcapone
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2169213

Group type: EXPERIMENTAL
Intervention: 150 IU.kg‐1.day‐1 heparin (group HEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.2 mg.kg‐1.day‐1 enoxaparin (group ENX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 mg.kg‐1.day‐1 enoxaparin with 5 ng.kg‐1.min‐1 prostaglandin I2 (group ENX and PGI2)
Number of subjects: 0
Study: 6901189

Group type: EXPERIMENTAL
Intervention: Diet with no added sugar for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular baby food with additional sugar for 3 months
Number of subjects: 40
Study: 30991255

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27444991

Group type: EXPERIMENTAL
Intervention: Continuous saline bladder irrigation (CSBI) at 2000 mL/h for the first 1 hour, then 1000 mL/h for 2 hours, followed by 500 mL/h for 15 hours
Number of subjects: 250

Group type: COMPARATOR
Intervention: Single immediate instillation of mitomycin C (MMC)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Continuous saline bladder irrigation (CSBI)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 250
Study: 25976647

Group type: EXPERIMENTAL
Intervention: Group 1: 20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Group 2: 10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2 mg per day Z; Macushield; Macuhealth
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Group 3: 17 mg per day MZ, 3 mg per day L, 2 mg per day Z
Number of subjects: 67
Study: 23328337

Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 20722060

Group type: EXPERIMENTAL
Intervention: Hispanic patients with IPAA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-Hispanic white patients with IPAA
Number of subjects: 36
Study: 19832788

Group type: EXPERIMENTAL
Intervention: 15 minutes of moderate intensity stationary cycling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive seating (control)
Number of subjects: 20
Study: 17083064

Group type: EXPERIMENTAL
Intervention: Enalapril (520 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/d)
Number of subjects: 24
Study: 12950422

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10977396

Group type: EXPERIMENTAL
Intervention: Vaccination with the 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No vaccination and treatment
Number of subjects: 1000
Study: 8783051

Group type: EXPERIMENTAL
Intervention: Colgate Total
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crest regular
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crest Tartar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate regular
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate 0-6 gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 1731288

Group type: EXPERIMENTAL
Intervention: Routine weekly cervical examinations at term (from 37 weeks until delivery)
Number of subjects: 604

Group type: COMPARATOR
Intervention: No examination group (routine examinations not performed)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Routine weekly cervical examinations at term
Number of subjects: 604

Group type: COMPARATOR
Intervention: No examination group
Number of subjects: 604
Study: 2864891

Group type: EXPERIMENTAL
Intervention: Ipratropium alone (160 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fenoterol alone (400 micrograms) after placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium with fenoterol
Number of subjects: 10
Study: 30565892

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU monthly)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 30180683

Group type: EXPERIMENTAL
Intervention: Multi-vowel stimuli with low broadband error, high vowel diversity, and high vowel discriminability.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confusable vowels that were most susceptible to filtering.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Least susceptible vowels.
Number of subjects: 0
Study: 26757045

Group type: EXPERIMENTAL
Intervention: DPT depot extract (0.0625-0.75 SPT units)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 25239216

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (maltodextrin solution)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON) group (placebo solution)
Number of subjects: 24
Study: 22873191

Group type: EXPERIMENTAL
Intervention: Interest in learning about 12-Step groups
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clinicians' perception of the helpfulness of 12-Step groups
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Severity of patients' problems with substance abuse
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Didactic and experiential education for clinicians in substance abuse and mutual aid
Number of subjects: 6
Study: 20157677

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (SB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt (AP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preparation walls (pulpal, axial, gingival)
Number of subjects: 0
Study: 17306498

Group type: EXPERIMENTAL
Intervention: Cellular immunotherapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: New agents for treating castration-resistant prostate cancer
Number of subjects: 0
Study: 15674305

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sterol supplementation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 11879139

Group type: EXPERIMENTAL
Intervention: Topical unoprostone
Number of subjects: 24

Group type: COMPARATOR
Intervention: ET-1 administration
Number of subjects: 24
Study: 10673968

Group type: EXPERIMENTAL
Intervention: Patient treatment preferences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study: 8822422

Group type: EXPERIMENTAL
Intervention: Org 32489 (Puregon)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Urinary FSH (Metrodin)
Number of subjects: 99
Study: 2138477

Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin i.v. weekly (Awkly)
Number of subjects: 166

Group type: COMPARATOR
Intervention: 50 mg 4‐epidoxorubicin biweekly (EPIbiwkly)
Number of subjects: 166
Study: 6766411

Group type: EXPERIMENTAL
Intervention: Phosphate infusions (62 ± 5 mmol sodium phosphate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized conventional treatment alone
Number of subjects: 40
Study: 31860326

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 149
Study: 29974963

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg administered subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30
Study: 28327692

Group type: EXPERIMENTAL
Intervention: Immediate post-extractive implants
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Immediate-delayed implants at 6 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Delayed implants after 4 months
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 210
Study: 25821849

Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5000 µg F/g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice (1100 µg F/g)
Number of subjects: 12
Study: 23543359

Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Usual clinic services (Control)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Prime Time intervention (dose-response analysis)
Number of subjects: 253
Study: 22575317

Group type: EXPERIMENTAL
Intervention: Highest heart rate tertile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest heart rate tertile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with AF at baseline
Number of subjects: 0
Study: 19848209

Group type: EXPERIMENTAL
Intervention: Sanqidan Granules (SQD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral hypoglycemic drugs (glipizide, pioglitazone, metformin) and antihypertensive drug (nifedipine)
Number of subjects: 45